Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.93 [0.83, 1.04]
5 studies · 2006 participants
Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.92 [0.7, 1.21]
1 study · 242 participants
Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

Overall survival (OS) · recurrent platinum‐resistant EOC

Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.96 [0.77, 1.19]
6 studies · 1995 participants
Moderate